Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients.

scientific article published on 7 April 2019

Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients. is …
instance of (P31):
review articleQ7318358
scholarly articleQ13442814

External links are
P356DOI10.1155/2019/4674560
P932PMC publication ID6507153
P698PubMed publication ID31179323

P50authorGaia PelusoQ89800694
Gianluca MinieriQ114536993
Concetta Anna DodaroQ114536994
Massimiliano CretaQ56849247
Nicola CarlomagnoQ59656795
Armando CalogeroQ85237107
Silvia AngelettiQ87834640
Paola IncollingoQ89800691
Massimo CiccozziQ28743803
Caterina SagnelliQ42257713
Evangelista SagnelliQ41549310
P2093author name stringMaria Candida
P2860cites workAn update on the treatment options for HBV/HCV coinfectionQ47586705
Characteristics of patients with hepatitis C virus-related chronic liver diseases just before the era of oral direct-acting antiviral therapy in ItalyQ49712889
Malfunctions of robotic system in surgery: role and responsibility of surgeon in legal point of view.Q50867414
Informed consent in robotic surgery: quality of information and patient perception.Q53736466
Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial.Q54261696
Micro-RNAs in hepatitis B virus-related chronic liver diseases and hepatocellular carcinomaQ57491234
EASL Recommendations on Treatment of Hepatitis C 2015Q58324800
Direct-acting antivirals and hepatitis B virus (HBV) reactivation in co-infected HBV/HCV kidney-transplant recipientsQ59350534
Transplantation of hepatitis C virus (HCV) antibody positive, nucleic acid test negative donor kidneys to HCV negative patients frequently results in seroconversion but not HCV viremiaQ59356129
Suboptimal kidney: the experience of a single transplant unitQ79996734
Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantationQ80572083
The finding of vascular and urinary anomalies in the harvested kidney for transplantationQ80783151
Healing of surgical incision in kidney transplantation: a single transplant center's experienceQ83937496
KidneyQ87056246
New food approaches to reduce and/or eliminate increased gastric acidity related to gastroesophageal pathologiesQ88577052
Interventions for dialysis patients with hepatitis C virus (HCV) infectionQ24187826
Lactoferrin Adsorbed onto Biomimetic Hydroxyapatite Nanocrystals Controlling - In Vivo - the Helicobacter pylori InfectionQ27335157
Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalenceQ29616009
Sofosbuvir for previously untreated chronic hepatitis C infectionQ29620137
Epidemiological and clinical scenario of chronic liver diseases in Italy: Data from a multicenter nationwide surveyQ31107505
Serum alanine aminotransferase in hepatitis c screening of patients on hemodialysisQ31827501
Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized TrialQ33167896
Overlapping pathways to transplant glomerulopathy: chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathyQ33395896
Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study GroupQ33464499
Hepatitis C virus infection and dialysis: 2012 updateQ33710828
Hepatic flares in chronic hepatitis C: spontaneous exacerbation vs hepatotropic viruses superinfectionQ33735206
Rare multiple primary malignancies among surgical patients-a single surgical unit experienceQ33768627
Intraperitoneal dedifferentiated liposarcoma showing MDM2 amplification: case report.Q34465551
Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal womenQ34589830
Effect of kidney transplantation on outcomes among patients with hepatitis CQ35012447
Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictorsQ35146790
Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veteransQ35528192
Management of telaprevir-based triple therapy for hepatitis C virus recurrence post liver transplantQ35626794
Immunosuppression and Multiple Primary Malignancies in Kidney-Transplanted Patients: A Single-Institute StudyQ35818080
Epidemiology and clinical significance of hepatotropic infections in dialysis patients. Recent evidenceQ35910416
Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus InfectionQ36077546
Difficult vascular conditions in kidney transplantationQ36498706
Treatment of hepatitis C virus infection (HCV) after renal transplantation: implications for HCV-positive dialysis patients awaiting a kidney transplantQ36622506
Primary extraosseous Ewing sarcoma of the lung in childrenQ36791086
Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.Q36870864
The kidney transplant recipient with hepatitis C infection: pre- and posttransplantation treatmentQ36910603
Hepatitis C virus and kidney diseaseQ37229019
Complicated diverticulitis in kidney transplanted patients: analysis of 717 casesQ41731026
Prevention of fluid effusion in kidney transplantation with the use of hemostatic biomaterialsQ41731042
Total colectomy for cancer: analysis of factors linked to patients' age.Q41757591
EASL recommendations on treatment of hepatitis C 2014.Q42219300
Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfected patientsQ42222997
Factors influencing liver fibrosis and necroinflammation in HIV/HCV coinfection and HCV monoinfectionQ42255783
Benefits associated with antiviral treatment in kidney allograft recipients with chronic hepatitis B virus infection.Q42978334
Successful treatment of chronic HCV infection should not preclude kidney donation to an HCV negative recipient.Q42994735
Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients.Q42995926
Long-Term Experience With Kidney Transplantation From Hepatitis C-Positive Donors Into Hepatitis C-Positive RecipientsQ43000880
Kidney transplantation from a donor who is HCV antibody positive and HCV-RNA negativeQ43001383
Impact of immunosuppressive therapy on hepatitis C infection after renal transplantation.Q43032343
Trial of Transplantation of HCV-Infected Kidneys into Uninfected RecipientsQ43038211
Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritisQ43039778
Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipientsQ43040103
Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimusQ43964552
Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New ZealandQ44177155
Impact of hepatitis B and C virus on kidney transplantation outcomeQ44231771
Older kidneys donor transplantation: five years' experience without biopsy and using clinical laboratory and macroscopic anatomy evaluation.Q44367232
Sex difference in the interaction of alcohol intake, hepatitis B virus, and hepatitis C virus on the risk of cirrhosisQ45324819
Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective studyQ45356128
Association of hepatitis C virus infection with risk of ESRD: a population-based studyQ45357852
Hepatitis C virus infection and de novo glomerular lesions in renal allograftsQ45731872
Transplantation of Renal Allografts From Organ Donors Reactive for HCV Antibodies to HCV-Negative Recipients: Safety and Clinical Outcome.Q45967412
Wound complications after kidney transplantation in nondiabetic patients.Q46001916
Treatment of Hepatitis C Infection in Renal Transplant Recipients: The Long Wait Is OverQ46080993
Tacrolimus and cyclosporin doses and blood levels in hepatitis C and alcoholic liver disease patients after liver transplantationQ46831252
Gender differences in chronic liver diseases in two cohorts of 2001 and 2014 in ItalyQ47573260
Incidence of breast cancer in Italy: mastectomies and quadrantectomies performed between 2000 and 2005Q37268370
Hepatitis C therapy before and after liver transplantationQ37282557
Early Results of Pilot Study Using Hepatitis C Virus (HCV) Positive Kidneys to Transplant HCV Infected Patients with End-Stage Renal Disease Allowing for Successful Interferon-Free Direct Acting Antiviral Therapy after TransplantationQ37527974
Hepatitis C virus and nonliver solid organ transplantation.Q38061560
The rapid evolution of treatment strategies for hepatitis C.Q38204657
Dendritic cell-based vaccines: clinical applications in breast cancer.Q38206821
Perioperative care of elderly outpatient: a reviewQ38246630
Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatmentQ38286904
Surgery of the primary tumor in de novo metastatic breast cancer: To do or not to do?Q38559952
Etiological factors of chronic hepatitis in Italy: a 2014 national surveyQ38679799
What indication, morbidity and mortality for central pancreatectomy in oncological surgery? A systematic review.Q38680812
HCV and the kidneyQ38685571
Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlledQ38747790
The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation.Q38757351
Clinical impact of the hepatitis C virus mutations in the era of directly acting antiviralsQ38779980
Hepatitis C Virus Infection in Chronic Kidney DiseaseQ38812607
Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C.Q38971057
Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C.Q39049269
Safety and Efficacy of Treatment of Hepatitis C in Kidney Transplant Recipients With Directly Acting Antiviral AgentsQ39051675
Chronic hepatitis C and chronic kidney disease: Advances, limitations and unchartered territoriesQ39096731
Successful Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Ledipasvir in Renal Transplant RecipientsQ39519539
Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal DiseaseQ39920614
Direct-acting antiviral agent efficacy and safety in renal transplant recipients with chronic hepatitis C virus infection: A PRISMA-compliant studyQ40107697
Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patientsQ40113130
Successful Treatment of Hepatitis C in Renal Transplant Recipients With Direct-Acting Antiviral AgentsQ40278284
Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study.Q40278746
Efficacy and Safety of Sofosbuvir-Based Antiviral Therapy to Treat Hepatitis C Virus Infection After Kidney Transplantation.Q40297644
Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR <30 ml/minQ40303431
TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotype.Q40482870
Use of HCV+ Donors Does Not Affect HCV Clearance With Directly Acting Antiviral Therapy But Shortens the Wait Time to Kidney TransplantationQ40586756
Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-acting Antiviral AgentsQ40620558
Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function.Q40774514
Impact of PNPLA3 variants on liver histology of 168 patients with HIV infection and chronic hepatitis C.Q40819897
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 studyQ40957442
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P407language of work or nameEnglishQ1860
P921main subjectkidney transplantationQ740909
eradication of infectious diseasesQ1347969
HepacivirusQ2082778
chronic hepatitis CQ55779873
transplant recipientQ58659328
sustained virologic responseQ70490546
antiviral agentQ40207875
P304page(s)4674560
P577publication date2019-04-07
P1433published inBioMed Research InternationalQ17509958
P1476titleEradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients
P478volume2019

Reverse relations

cites work (P2860)
Q92716402Colorectal Cancer in the Elderly Patient: The Role of Neo-adjuvant Therapy
Q92544060Differential Diagnosis: Retroperitoneal Fibrosis and Oncological Diseases
Q92410137Erratum to "Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients"
Q90567346Infectious Complications Following Kidney Transplantation-A Focus on Hepatitis C Infection, Cytomegalovirus Infection and Novel Developments in the Gut Microbiota
Q92154701Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention